Drugs & Therapy Perspectives

, Volume 15, Issue 1, pp 1–5 | Cite as

Temozolomide may improve the outlook for patients with recurrent malignant gliomas

New drugs and disease management


Thalidomide Temozolomide Malignant Glioma Glioblastoma Multiforme Anaplastic Astrocytoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Temodar prescribing information. Kenilworth (NJ): Schering Corporation, 1999Google Scholar
  2. 2.
    Hvizdos K, Goa K. Temozolomide. CNS Drugs 1999 Sep; 12(3): 237–43CrossRefGoogle Scholar
  3. 3.
    Partial backing for temozolomide from US ODAC. Pharma Marketletter 1999 Jan 18: 19Google Scholar
  4. 4.
    Newlands E. Temozolomide. CNS Drugs 1999 Sep; 12(3): 245CrossRefGoogle Scholar
  5. 5.
    Friedman H. Temozolomide. CNS Drugs 1999 Sep; 12(3): 244CrossRefGoogle Scholar
  6. 6.
    Biochemical actions and clinical use of temozolomide. Pharm J 1999 Apr 3; 262: 468Google Scholar
  7. 7.
    Prados M, Yung A, Chang S, et al. A phase II trial of Temodal® (temozolomide) in patients with anaplastic astrocytoma at first relapse [abstract 533]. 35th Proc Am Soc Clin Oncol 1999 May; 18: 139aGoogle Scholar
  8. 8.
    Schering Temodal® tumor response supports astrocytoma, not glioblastoma. FDC Pink 1999 Jan 18; 61: 3-4Google Scholar
  9. 9.
    Yung A, Levin VA, Albright R, et al. Randomized trial of Temodal vs. procarbazine in glioblastoma multiforme at first relapse [abstract 532]. 35th Proc Am Soc Clin Oncol 1999 May; 18: 139aGoogle Scholar
  10. 10.
    British National Formulary No. 38. London: The Pharmaceutical Press, 1999 Sep: 386Google Scholar
  11. 11.
    Kaba S, Kyritisis, A. Recognition and management of gliomas. Drugs 1997 Feb; 53(2): 235–44PubMedCrossRefGoogle Scholar
  12. 12.
    American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1999; 991-2Google Scholar
  13. 13.
    New Ethicals Catalogue. Auckland: Adis International, 1999 May: 264Google Scholar
  14. 14.
    Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 1998 Dec; 16: 3851–7PubMedGoogle Scholar
  15. 15.
    Newlands ES, O’Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer A 1996 Dec; 32A: 2236–41PubMedCrossRefGoogle Scholar
  16. 16.
    Osoba D, Levin V, Yung WKA, et al. Health-related quality of life benefits in patients with recurrent anaplastic astrocytoma treated with temozolomide [abstract 1496]. 34th Proc Am Soc Clin Oncol 1998 May; 17: 388aGoogle Scholar
  17. 17.
    Osoba D, Brada M, Yung WKA. Health-related quality of life benefits of treatment with temozolomide versus procarbazine in patients with glioblastoma multiforme [abstract 541]. 35th Proc Am Soc Clin Oncol 1999 May; 18: 141aGoogle Scholar
  18. 18.
    Bower M, Newlands ES, Bleehan NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997 Oct; 29A(7): 940–2Google Scholar

Copyright information

© Adis International Limited 2000

Personalised recommendations